Teva and sanofi present new positive phase 2b study results at ecco 2025 reinforcing best-in-class potential of duvakitug (anti-tl1a) in ulcerative colitis and crohn's disease

New detailed data from the relieve uccd study support overall efficacy and safety of duvakitug in all pre-specified subgroups across the different doses new endpoints presented include findings on clinical and endoscopic outcomes and histological- endoscopic mucosal improvement findings to form the basis for a phase 3 program, anticipated to start in h2 2025 parsippany, n.j. and paris, feb. 22, 2025 (globe newswire) -- teva pharmaceuticals, a u.s. affiliate of teva pharmaceutical industries ltd.
TEVA Ratings Summary
TEVA Quant Ranking